Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.
Department of Radiology, University of Rochester Medical Center, Rochester, NY, USA.
Breast Dis. 2022;41(1):255-260. doi: 10.3233/BD-210041.
Inflammatory breast cancer (IBC) is a rare variety of breast cancer accounting for two percent of breast cancer diagnoses in the United States. It is characterized by peau d'orange, breast edema and erythema on physical examination and dermal lymphatic invasion by tumor emboli on histological examination. Micrometastases to lymphatics and bone marrow at the time of diagnosis and angiogenic properties of IBC explain the high propensity of this cancer to relapse and metastasize, its aggressiveness and poor prognosis. Preoperative sequential anthracycline and taxane (plus trastuzumab and pertuzumab if HER2-positive) based chemotherapy is the current standard of care for IBC. We herein report a case of stage IIIC triple-negative IBC treated with pembrolizumab plus chemotherapy based neoadjuvant therapy with a complete clinical and complete pathological response. This is the first case of triple-negative IBC treated with this regimen reported in the literature, thereby providing clinical data on the tolerability and efficacy of pembrolizumab plus chemotherapy based neoadjuvant regimen for the treatment of IBC.
炎性乳腺癌（IBC）是一种罕见的乳腺癌，占美国乳腺癌诊断的 2%。其特征是体检时橘皮样外观、乳房水肿和红斑，组织学检查时肿瘤栓子侵犯皮肤淋巴管。诊断时微转移至淋巴管和骨髓，以及 IBC 的血管生成特性解释了这种癌症易复发和转移、侵袭性和预后不良的原因。术前序贯蒽环类和紫杉类（如果 HER2 阳性则加用曲妥珠单抗和帕妥珠单抗）化疗是 IBC 的当前标准治疗方法。本文报告了一例 IIIC 期三阴性 IBC 患者接受帕博利珠单抗联合化疗的新辅助治疗，达到完全临床和完全病理缓解。这是文献中首例报道的三阴性 IBC 患者接受该方案治疗，从而为帕博利珠单抗联合化疗新辅助方案治疗 IBC 的耐受性和疗效提供了临床数据。
